Biotech News

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

HOOKIPA Pharma Inc. (HOOK)HOOKIPA Pharma Inc.Partnership

HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”).

In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agreement”) with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA’s assets primarily related to or necessary for the conduct of HOOKIPA’s HB-400 program, currently in clinical development for the treatment of hepatitis B virus, and certain of HOOKIPA’s assets related to HOOKIPA’s HB-500 program, currently in clinical development for the treatment of human immunodeficiency virus. HOOKIPA has been developing the HB-400 and HB-500 programs in collaboration with Gilead pursuant to the collaboration and license agreement with Gilead. The closing of the Asset Purchase Agreement occurred on October 30, 2025.

Availability of Other Information About HOOKIPA Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com , OTC Markets filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.

For further information, please contact:

Investors :

ir@hookipapharma.com

Related news

ERASErasca2026-11-17 23:40 EST

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

REGNRegeneron Pharmaceuticals2026-11-19 12:00 EST

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

PRLDPrelude Therapeutics2026-11-16 12:01 EST

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SNYSanofi2026-11-12 17:30 EST

Sanofi: Information concerning the total number of voting rights and shares - October 2026

CHRSCoherus BioSciences, Inc.2026-11-09 21:06 EST

Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

ZNTLZentalis2026-11-09 21:05 EST

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

HOOKIPA Pharma Inc.

Arenaviral Immunotherapy Platform HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines. HB-700 for KRAS-Mutated Cancers HB-700 is a multi-antigen therapy directed at...

Recent company news

Stock data

Close
1.15 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States